Immunome Inc. (IMNM) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US45257U1088
Immunome Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 6.94 m USD |
| Operating income | -224.11 m USD |
| EBIT | -212.39 m USD |
| Net income | -212.39 m USD |
| Diluted EPS – continuing operations | -2.43 USD |
Full history since 2018, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Immunome Inc.
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
More stocks
- BIOCRYST PHARMACEUTICALS INC (BCRX)
- Progyny, Inc. (PGNY)
- Beijing Jetsen Tech Co (300182.SZ)
- Triputra Agro Persada Tbk PT (TAPG.JK)
- ManpowerGroup Inc. (MAN)
- Pony AI Inc. American Depositary Shares (PONY)
- Socionext Inc (6526.T)
- Denison Mines Corp (DML.TO)
- Konica Minolta Inc (4902.T)
- TSE Co. Ltd (131290.KQ)
- PALVELLA THERAPEUTICS, INC. (PVLA)
- Zhejiang Weixing Industrial Development Co Ltd (002003.SZ)
Not investment advice. All data without warranty, price as of 22.10.2026. Details in the risk notice.